National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Overview of Analytic Approach and Results." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
55
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

MELANOMA

 

 

Patients

90

500

7

360

MULTIPLE SCLEROSIS

 

 

Patients

90

500

15

360

MYCOBACTERIUM TUBERCULOSIS

 

 

High-risk populations

90

50

15

360

 

Universal in multidrug-resistant areas

60

50

15

360

NEISSERIA GONORRHEA

 

 

12-year-olds

50

50

15

360

NEISSERIA MENINGITIDIS B

 

 

Infants

90

50

7

300

PARAINFLUENZA

 

 

Infants

90

50

7

300

 

12-year-old females

90 or 10

50

7

360

RESPIRATORY SYNCTIAL VIRUS

 

 

Infants

90

50

7

360

 

12-year-old females

50

50

7

360

RHEUMATOID ARTHRITIS

 

 

Patients

90

500

15

360

ROTAVIRUS

 

 

Infants

90

50

3

120

SHIGELLA

 

 

Infants

90

50

7

240

 

Travelers

30

50

7

240

STREPTOCOCCUS GROUP A

 

 

Infants

90

50

15

400

STREPTOCOCCUS GROUP B

 

 

High-risk people, and either:

30

50

7

See below

 

12-year-old females or

50

50

7

300

 

Women in their first pregnancy

10 or 90

50

7

400

STREPTOCOCCUS PNEUMONIA

 

 

Infants

90

50

3

240

 

65-year-olds

60

50

3

240

Page
55
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)